Effect of PMX-DHP for sepsis due to ESBL-producing E. coli in an extremely low-birthweight infant

Naoto Nishizaki; Mayu Nakagawa; Satoshi Hara; Hisayuki Oda; Masato Kantake; Kaoru Obinata; Yuki Uehara; Keiichi Hiramatsu; Toshiaki Shimizu

doi:10.1111/ped.12825

Effect of PMX-DHP for sepsis due to ESBL-producing E. coli in an extremely low-birthweight infant

Naoto Nishizaki, Mayu Nakagawa, Satoshi Hara, Hisayuki Oda, Masato Kantake, Kaoru Obinata, Yuki Uehara, Keiichi Hiramatsu, Toshiaki Shimizu

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

Abstract

We report a case of early onset sepsis caused by (CTX for cefotaximase and M for Munich)-type extended-spectrum β-lactamase-producing Escherichia coli (ESBL E. coli) in a preterm infant weighing 601 g. He was given meropenem and treated for endotoxin absorption with polymyxin B-immobilized fibers with only 8 mL of priming volume. The patient survived without any short-term neurological or respiratory sequelae. The choice of antibiotics is particularly important in seriously ill neonates with sepsis due to ESBL-producing organisms. Polymyxin B hemoperfusion might be an innovative therapy for severe neonatal sepsis and could improve outcome even in an extremely low-birthweight infant.

Original language	English
Pages (from-to)	411-414
Number of pages	4
Journal	Pediatrics International
Volume	58
Issue number	5
DOIs	https://doi.org/10.1111/ped.12825
Publication status	Published - 01-05-2016
Externally published	Yes

All Science Journal Classification (ASJC) codes

Pediatrics, Perinatology, and Child Health

Access to Document

10.1111/ped.12825

Cite this

@article{2d72bb0b4f0346eca6854a5436bd8552,

title = "Effect of PMX-DHP for sepsis due to ESBL-producing E. coli in an extremely low-birthweight infant",

abstract = "We report a case of early onset sepsis caused by (CTX for cefotaximase and M for Munich)-type extended-spectrum β-lactamase-producing Escherichia coli (ESBL E. coli) in a preterm infant weighing 601 g. He was given meropenem and treated for endotoxin absorption with polymyxin B-immobilized fibers with only 8 mL of priming volume. The patient survived without any short-term neurological or respiratory sequelae. The choice of antibiotics is particularly important in seriously ill neonates with sepsis due to ESBL-producing organisms. Polymyxin B hemoperfusion might be an innovative therapy for severe neonatal sepsis and could improve outcome even in an extremely low-birthweight infant.",

author = "Naoto Nishizaki and Mayu Nakagawa and Satoshi Hara and Hisayuki Oda and Masato Kantake and Kaoru Obinata and Yuki Uehara and Keiichi Hiramatsu and Toshiaki Shimizu",

note = "Publisher Copyright: {\textcopyright} 2015 Japan Pediatric Society",

year = "2016",

month = may,

day = "1",

doi = "10.1111/ped.12825",

language = "English",

volume = "58",

pages = "411--414",

journal = "Pediatrics International",

issn = "1328-8067",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

TY - JOUR

T1 - Effect of PMX-DHP for sepsis due to ESBL-producing E. coli in an extremely low-birthweight infant

AU - Nishizaki, Naoto

AU - Nakagawa, Mayu

AU - Hara, Satoshi

AU - Oda, Hisayuki

AU - Kantake, Masato

AU - Obinata, Kaoru

AU - Uehara, Yuki

AU - Hiramatsu, Keiichi

AU - Shimizu, Toshiaki

PY - 2016/5/1

Y1 - 2016/5/1

N2 - We report a case of early onset sepsis caused by (CTX for cefotaximase and M for Munich)-type extended-spectrum β-lactamase-producing Escherichia coli (ESBL E. coli) in a preterm infant weighing 601 g. He was given meropenem and treated for endotoxin absorption with polymyxin B-immobilized fibers with only 8 mL of priming volume. The patient survived without any short-term neurological or respiratory sequelae. The choice of antibiotics is particularly important in seriously ill neonates with sepsis due to ESBL-producing organisms. Polymyxin B hemoperfusion might be an innovative therapy for severe neonatal sepsis and could improve outcome even in an extremely low-birthweight infant.

AB - We report a case of early onset sepsis caused by (CTX for cefotaximase and M for Munich)-type extended-spectrum β-lactamase-producing Escherichia coli (ESBL E. coli) in a preterm infant weighing 601 g. He was given meropenem and treated for endotoxin absorption with polymyxin B-immobilized fibers with only 8 mL of priming volume. The patient survived without any short-term neurological or respiratory sequelae. The choice of antibiotics is particularly important in seriously ill neonates with sepsis due to ESBL-producing organisms. Polymyxin B hemoperfusion might be an innovative therapy for severe neonatal sepsis and could improve outcome even in an extremely low-birthweight infant.

UR - http://www.scopus.com/inward/record.url?scp=84952674137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952674137&partnerID=8YFLogxK

U2 - 10.1111/ped.12825

DO - 10.1111/ped.12825

M3 - Article

AN - SCOPUS:84952674137

SN - 1328-8067

VL - 58

SP - 411

EP - 414

JO - Pediatrics International

JF - Pediatrics International

IS - 5

ER -

Effect of PMX-DHP for sepsis due to ESBL-producing E. coli in an extremely low-birthweight infant

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this